You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Nurse View: Tailoring Treatments in Triple Negative Breast Cancer

  • Authors: Janice Tran, PhD, NP-C, AOCNP, CBCN; Sarah Donahue, MPH, NP, AOCNP
  • CE Released: 11/23/2020
  • Valid for credit through: 11/23/2021
Start Activity

Target Audience and Goal Statement

This activity is intended for nurses and nurse practitioners

The goal of this activity is to improve the knowledge and competence of nurses surrounding the use of immunotherapy-based treatments and poly (ADP-ribose) polymerase (PARP) inhibitors in the management of patients with triple-negative breast cancer (TNBC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of biomarkers in identifying patients with TNBC eligible to receive PARP inhibitors or immune checkpoint inhibitor-based therapy
    • Optimal therapy for patients with TNBC based on stage, molecular testing, and comorbidities
  • Have greater competence related to
    • Managing treatment-related adverse events (TRAEs) associated with treatments used in TNBC


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Janice Tran, PhD, NP-C, AOCNP, CBCN

    Texas Oncology
    Houston, Texas


    Disclosure: Janice Tran, PhD, NP-C, AOCNP, CBCN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Biotheranostics; Eisai Pharmaceuticals; GlaxoSmithKline; Novartis; Seattle Genetics
    Served as a speaker or a member of a speakers bureau for: Novartis

  • Sarah Donahue, MPH, NP, AOCNP

    UCSF Medical Center
    San Francisco, California


    Disclosure: Sarah Donahue, MPH, NP, AOCNP, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis


  • Victoria Phoenix, BS

    Medical Education Director, Medscape, LLC


    Disclosure: Victoria Phoenix has disclosed no relevant financial relationships.

  • Yoji Yamaguchi, MA

    Associate Scientific Content Manager, Medscape, LLC


    Disclosure: Yoji Yamaguchi has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Nurse View: Tailoring Treatments in Triple Negative Breast Cancer

Authors: Janice Tran, PhD, NP-C, AOCNP, CBCN; Sarah Donahue, MPH, NP, AOCNPFaculty and Disclosures

CE Released: 11/23/2020

Valid for credit through: 11/23/2021


ALT = alanine aminotransferase
AST = aspartate aminotransferase
AUC = area under the curve
CPS = combined positive score
CT = computed tomography
DCR = disease control rate
DFI = disease-free interval
DOR = duration of response
ECOG PS = Eastern Cooperative Oncology Group performance status
ER = estrogen receptor
FNA = fine needle aspiration
gBRCA = germline BRCA
HER2 = human epidermal growth factor receptor 2
HRQoL = health-related quality of life
IC = immune cell
ITC = isolated tumor cell
ITT = intent-to-treat
IV = intravenous
mTNBC = metastatic triple-negative breast cancer
NCCN = National Comprehensive Cancer Network
ORR = objective response rate
OS = overall survival
PARP = poly (ADP-ribose) polymerase
PD-L1 = programmed death-ligand 1
PET = positron emission tomography
PFS = progression-free survival
PO = by mouth
PR = progesterone receptor
RCT = randomized controlled trial
TIL = tumor infiltrating lymphocyte
TNBC = triple-negative breast cancer
TRAE = treatment-related adverse event

« Return to: Nurse View: Tailoring Treatments in Triple Negative Breast Cancer
  • Print